Changes in Human In vivo Serotonin and Dopamine Transporter Availabilities during Chronic Antidepressant Administration

[1]  M. Kuhar,et al.  Rate of binding of various inhibitors at the dopamine transporter in vivo , 1995, Psychopharmacology.

[2]  I. Podreka,et al.  β-CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo , 2005, Journal of Neural Transmission / General Section JNT.

[3]  C. Sánchez,et al.  Comparison of the Effects of Antidepressants and Their Metabolites on Reuptake of Biogenic Amines and on Receptor Binding , 1999, Cellular and Molecular Neurobiology.

[4]  M. Fujita,et al.  Enhancement of [123I]β-CIT binding in the striatum with clomipramine: Is there a serotonin-dopamine interaction? , 1997, European Journal of Nuclear Medicine.

[5]  J. Hyttel.  Neurochemical characterization of a new potent and selective serotonin uptake inhibitor: Lu 10-171 , 1977, Psychopharmacology.

[6]  J. Hyttel,et al.  Biochemical effects and drug levels in rats after long-term treatment with the specific 5-HT-uptake inhibitor, citalopram , 2004, Psychopharmacology.

[7]  Alan A. Wilson,et al.  Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. , 2001, The American journal of psychiatry.

[8]  M Fujita,et al.  Sex differences in [123I]β‐CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers , 2001, Synapse.

[9]  N. Richard,et al.  A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. , 2001, Clinical therapeutics.

[10]  A. Clayton,et al.  Substitution of an SSRI with bupropion sustained release following SSRI-induced sexual dysfunction. , 2001, The Journal of clinical psychiatry.

[11]  J D Malley,et al.  In vivo microdialysis assessment of extracellular serotonin and dopamine levels in awake monkeys during sustained fluoxetine administration , 2000, Synapse.

[12]  A. Schatzberg.  New indications for antidepressants. , 2000, The Journal of clinical psychiatry.

[13]  M Slifstein,et al.  In vivo quantification of brain serotonin transporters in humans using [11C]McN 5652. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  J. Seibyl,et al.  Elevated central serotonin transporter binding availability in acutely abstinent cocaine-dependent patients. , 2000, The American journal of psychiatry.

[15]  M. Frye,et al.  The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. , 2000, The Journal of clinical psychiatry.

[16]  J. A. Johnston,et al.  Evaluation of sexual functioning in depressed outpatients: a double-blind comparison of sustained-release bupropion and sertraline treatment. , 2000, Journal of clinical psychopharmacology.

[17]  A Frazer,et al.  Effects of Chronic Antidepressant Treatments on Serotonin Transporter Function, Density, and mRNA Level , 1999, The Journal of Neuroscience.

[18]  B. Beer,et al.  Clinical development of citalopram. , 1999, Journal of Clinical Psychopharmacology.

[19]  R. Rosen,et al.  Effects of SSRIs on sexual function: a critical review. , 1999, Journal of clinical psychopharmacology.

[20]  S. Kasper,et al.  In vivo visualization of serotonin transporters in the human brain during fluoxetine treatment , 1999, European Neuropsychopharmacology.

[21]  Linda Carpenter,et al.  Reduced brain serotonin transporter availability in major depression as measured by [123I]-2β-carbomethoxy-3β-(4-iodophenyl)tropane and single photon emission computed tomography , 1998, Biological Psychiatry.

[22]  I G Zubal,et al.  Significance of nonuniform attenuation correction in quantitative brain SPECT imaging. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  R. Veith,et al.  Bupropion and desipramine increase dopamine transporter mrna expression in the ventral tegmental area/substantia nigra of rat brain , 1998, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[24]  R. Rosen,et al.  Bupropion as an antidote for serotonin reuptake inhibitor-induced sexual dysfunction. , 1998, The Journal of clinical psychiatry.

[25]  J. Karhu,et al.  Iodine-123 labeled nor-β-CIT as a potential tracer for serotonin transporter imaging in the human brain with single-photon emission tomography , 1997, European Journal of Nuclear Medicine.

[26]  P. Terry,et al.  Dopaminergic mediation of the discriminative stimulus effects of bupropion in rats , 1997, Psychopharmacology.

[27]  J. Modell,et al.  Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline , 1997, Clinical pharmacology and therapeutics.

[28]  J. Seibyl,et al.  Reproducibility of iodine-123-beta-CIT SPECT brain measurement of dopamine transporters. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  J. Feighner,et al.  Bupropion: a review of its mechanism of antidepressant activity. , 1995, The Journal of clinical psychiatry.

[30]  H. Meltzer,et al.  Effect of antidepressants on striatal and accumbens extracellular dopamine levels. , 1995, European journal of pharmacology.

[31]  D. Wong,et al.  Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. , 1995, Life sciences.

[32]  Robert B. Innis,et al.  Graphical, Kinetic, and Equilibrium Analyses of in vivo [123I]β-CIT Binding to Dopamine Transporters in Healthy Human Subjects , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[33]  B. Cooper,et al.  Evidence that the Acute Behavioral and Electrophysiological Effects of Bupropion (Wellbutrin®) Are Mediated by a Noradrenergic Mechanism , 1994, Neuropsychopharmacology.

[34]  M. Kuhar,et al.  Occupancy of the serotonin transporter by fluoxetine, paroxetine, and sertraline: In vivo studies with [125i]rti‐55 , 1994, Synapse.

[35]  P. McGuffin,et al.  Lack of effect of antidepressant drugs on the levels of mRNAs encoding serotonergic receptors, synthetic enzymes and 5HT transporter , 1994, Neuropharmacology.

[36]  L. Parsons,et al.  Serotonin and Dopamine Sensitization in the Nucleus Accumbens, Ventral Tegmental Area, and Dorsal Raphe Nucleus Following Repeated Cocaine Administration , 1993, Journal of neurochemistry.

[37]  S. Cheetham,et al.  [3H]Paroxetine binding in rat frontal cortex strongly correlates with [3H]5-HT uptake: Effect of administration of various antidepressant treatments , 1993, Neuropharmacology.

[38]  Robert B. Innis,et al.  Evaluation of the monoamine uptake site ligand [131I]methyl 3β-(4-Iodophenyl)-tropane-2β-carboxylate ([123I]β-CIT) in non-human primates: Pharmacokinetics, biodistribution and SPECT brain imaging coregistered with MRI , 1993 .

[39]  Marc Laruelle,et al.  SPECT imaging of dopamine and serotonin transporters with [123I]β‐CIT: Pharmacological characterization of brain uptake in nonhuman primates , 1993, Synapse.

[40]  Evaluation of the monoamine uptake site ligand [123I]methyl 3 beta-(4-iodophenyl)-tropane-2 beta-carboxylate ([123I]beta-CIT) in non-human primates: pharmacokinetics, biodistribution and SPECT brain imaging coregistered with MRI. , 1993, Nuclear medicine and biology.

[41]  D. Brunswick,et al.  Effect of repeated administration of antidepressants on serotonin uptake sites in limbic and neocortical structures of rat brain determined by quantitative autoradiography. , 1992, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[42]  P B Hoffer,et al.  [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane: high-affinity SPECT radiotracer of monoamine reuptake sites in brain. , 1991, Journal of medicinal chemistry.

[43]  E. Mcdaniel.  American Psychiatric Press Review of Clinical Psychiatry and the Law, Volume l—edited by Robert I. Simon, M.D.; Washington, D.C., American Psychiatric Press, 1990, 383 pages, $38.50 , 1990 .

[44]  G. Vauquelin,et al.  [3H]GBR 12935 Binding to Dopamine Uptake Sites in the Human Brain , 1989, Journal of neurochemistry.

[45]  J. Marcusson,et al.  High affinity [3H]paroxetine binding to serotonin uptake sites in human brain tissue , 1989, Brain Research.

[46]  R. Segraves,et al.  Effects of psychotropic drugs on human erection and ejaculation. , 1989, Archives of general psychiatry.

[47]  C. Pelizzari,et al.  Accurate Three‐Dimensional Registration of CT, PET, and/or MR Images of the Brain , 1989, Journal of computer assisted tomography.

[48]  J. Palacios,et al.  Autoradiography of antidepressant binding sites in the human brain: localization using [3h]imipramine and [3h]paroxetine , 1988, Neuroscience.

[49]  Marc Laruelle,et al.  Regional and subcellular localization in human brain of [3H]paroxetine binding, a marker of serotonin uptake sites , 1988, Biological Psychiatry.

[50]  S. Z. Langer,et al.  Effect of chronic treatment with selective monoamine oxidase inhibitors and specific 5-hydroxytryptamine uptake inhibitors on [3h]paroxetine binding to cerebral cortical membranes of the rat , 1987, Neuropharmacology.

[51]  S. Snyder,et al.  Selective labeling of serotonin uptake sites in rat brain by [3H]citalopram contrasted to labeling of multiple sites by [3H]imipramine. , 1987, The Journal of pharmacology and experimental therapeutics.

[52]  P. Benfield,et al.  Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. , 1986, Drugs.

[53]  J. Hyttel,et al.  Citalopram — Pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity , 1982, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[54]  G. Laakmann,et al.  The lack of effect of bupropion HCL (Wellbatrin) on the secretion of growth hormone and prolactin in humans. , 1982, Life sciences.

[55]  P. Whiteman,et al.  Bupropion fails to affect plasma prolactin and growth hormone in normal subjects. , 1982, British journal of clinical pharmacology.

[56]  M. Leach,et al.  The involvement of dopamine in the central actions of bupropion, a new antidepressant [proceedings]. , 1979, British journal of pharmacology.